<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00879164</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000640197</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC08C8</secondary_id>
    <secondary_id>08-006796</secondary_id>
    <secondary_id>NCI-2009-01133</secondary_id>
    <nct_id>NCT00879164</nct_id>
  </id_info>
  <brief_title>Stellate Ganglion Nerve Block in Treating Women With Hot Flashes</brief_title>
  <official_title>Pilot Evaluation of a Stellate Ganglion Block for the Treatment of Hot Flashes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: A stellate ganglion nerve block may help relieve hot flashes in women.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well a stellate ganglion nerve block works in&#xD;
      treating women with hot flashes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To evaluate the impact of stellate ganglion blockade on hot flash scores.&#xD;
&#xD;
        -  To evaluate the toxicity of stellate ganglion blockade.&#xD;
&#xD;
      OUTLINE: Patients undergo fluoroscopic-guided stellate ganglion blockade using bupivacaine&#xD;
      hydrochloride in week 1.&#xD;
&#xD;
      Patients complete a hot flash diary daily and a symptom experience diary weekly in weeks 1-7&#xD;
      and the Profile of Mood States questionnaire in weeks 1 and 7.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 2 months and then monthly for 1&#xD;
      year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in hot flash activity between baseline and week 7</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in quality of life, toxicity, and self-assessment items between baseline and week 7</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hot Flashes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Presence of hot flashes for ≥ 1 month prior to study registration&#xD;
&#xD;
               -  Hot flashes considered bothersome (defined by their occurrence of ≥ 28 times per&#xD;
                  week and of sufficient severity to make the patient desire therapeutic&#xD;
                  intervention)&#xD;
&#xD;
          -  Use of more conventional hot flash treatments (including newer antidepressants and&#xD;
             gabapentin) have failed to control hot flashes (as defined by the patient)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  Not of childbearing potential, as judged by the attending clinician&#xD;
&#xD;
          -  Able to complete questionnaires alone or with assistance&#xD;
&#xD;
          -  No evidence of an active malignancy&#xD;
&#xD;
          -  No von Willebrand's disease or other bleeding disorders&#xD;
&#xD;
          -  No allergy to chlorhexidine or bupivacaine&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent antineoplastic chemotherapy,&#xD;
             androgens, estrogens, or progestational agents&#xD;
&#xD;
               -  Tamoxifen, raloxifene, or aromatase inhibitors allowed provided the patient has&#xD;
                  been on a constant dose for ≥ 4 weeks and continues to receive medication during&#xD;
                  study treatment&#xD;
&#xD;
          -  More than 10 days since prior and no concurrent anticoagulants (e.g., aspirin,&#xD;
             clopidogrel, ticlopidine, or warfarin)&#xD;
&#xD;
               -  Concurrent heparin flushes for venous catheter allowed&#xD;
&#xD;
          -  No concurrent use of other agents (e.g., megestrol acetate, soy, clonidine, or&#xD;
             Bellergal) for treating hot flashes&#xD;
&#xD;
               -  Vitamin E, gabapentin, or antidepressants allowed provided the patient has been&#xD;
                  on a stable dose for &gt; 30 days and continues to receive medication during study&#xD;
                  treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles L. Loprinzi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>April 8, 2009</study_first_submitted>
  <study_first_submitted_qc>April 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2009</study_first_posted>
  <last_update_submitted>October 15, 2014</last_update_submitted>
  <last_update_submitted_qc>October 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hot flashes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

